MedPath

Understanding Daily Changes in BDD Risk Using Smartphones

Completed
Conditions
Body Dysmorphic Disorders
Registration Number
NCT04254575
Lead Sponsor
Massachusetts General Hospital
Brief Summary

Body dysmorphic disorder (BDD) is associated with high risk for suicide attempts (22-28%) and substance use disorders (49%), underscoring the importance of accurate, real-time risk detection in BDD. This study aims to use smartphone-based digital phenotyping to develop and validate unobtrusive, time-sensitive, and ecologically valid measures of key risk factors for suicide and substance misuse in BDD: negative affect states. As next steps, this research can be extended to detect risk transdiagnostically, with the goal of enabling just-in-time interventions to target suicide and substance misuse across psychiatric illnesses.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
87
Inclusion Criteria
  • Adults age >=18
  • Current primary diagnosis of BDD
  • BDD severity >= moderate
  • Living in US
  • English proficiency
  • Owns an Android or iOS (Apple) smartphone
  • Has regular Wifi-enabled internet access for data downloads
Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Self-reported anxiety intensity, rated from 1 (very slightly or not at all) to 5 (extremely)3 months

Ecological momentary assessment (EMA) of anxiety intensity, where higher scores indicated more severe anxiety.

Self-reported shame intensity, based on Positive and negative affect scale (PANAS) shame item, rated from 1 (very slightly or not at all) to 5 (extremely)3 months

Ecological momentary assessment (EMA) of shame intensity, where higher scores indicate more severe shame.

Self-reported negative affect intensity, based on Positive and negative affect scale (PANAS) negative affect items (averaged), rated from 1 (very slightly or not at all) to 5 (extremely)3 months

Ecological momentary assessment (EMA)-rated general negative affect intensity, where higher scores indicate more severe negative affect.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Massachusetts General Hospital

🇺🇸

Boston, Massachusetts, United States

Massachusetts General Hospital
🇺🇸Boston, Massachusetts, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.